These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 11430503)

  • 41. Correlation between oesophageal acid exposure and dyspeptic symptoms in patients with nonerosive reflux disease.
    Sarnelli G; De Giorgi F; Efficie E; Aprea G; Masone S; Savarese MF; Esposito I; Russo L; Cuomo R
    Eur J Gastroenterol Hepatol; 2008 Apr; 20(4):264-8. PubMed ID: 18334868
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparisons of the distribution of oesophageal acid exposure throughout the sleep period among the different gastro-oesophageal reflux disease groups.
    Dickman R; Parthasarathy S; Malagon IB; Jones P; Han B; Powers J; Fass R
    Aliment Pharmacol Ther; 2007 Jul; 26(1):41-8. PubMed ID: 17555420
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dyspepsia and gastroesophageal reflux disease (GERD): is there any correlation?
    Simadibrata M
    Acta Med Indones; 2009 Oct; 41(4):222-7. PubMed ID: 20737754
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Famotidine vs. omeprazole: a prospective randomized multicentre trial to determine efficacy in non-erosive gastro-oesophageal reflux disease.
    Fujiwara Y; Higuchi K; Nebiki H; Chono S; Uno H; Kitada K; Satoh H; Nakagawa K; Kobayashi K; Tominaga K; Watanabe T; Oshitani N; Arakawa T
    Aliment Pharmacol Ther; 2005 Jun; 21 Suppl 2():10-8. PubMed ID: 15943841
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Epidemiology and natural history of reflux disease.
    Nandurkar S; Talley NJ
    Baillieres Best Pract Res Clin Gastroenterol; 2000 Oct; 14(5):743-57. PubMed ID: 11003807
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [PPI-test].
    Takahashi M; Katayama Y; Suzuki K; Tajima A; Oka S; Koizumi K; Ichimura H; Kuwayama H
    Nihon Rinsho; 2007 May; 65(5):852-63. PubMed ID: 17511224
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Diagnostic value of potent acid inhibition in gastro-oesophageal reflux disease.
    Monés J
    Drugs; 2005; 65 Suppl 1():35-42. PubMed ID: 16335856
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of regurgitation on health-related quality of life in gastro-oesophageal reflux disease before and after short-term potent acid suppression therapy.
    Kahrilas PJ; Jonsson A; Denison H; Wernersson B; Hughes N; Howden CW
    Gut; 2014 May; 63(5):720-6. PubMed ID: 23831734
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prevalence of acid reflux in functional dyspepsia and its association with symptom profile.
    Tack J; Caenepeel P; Arts J; Lee KJ; Sifrim D; Janssens J
    Gut; 2005 Oct; 54(10):1370-6. PubMed ID: 15972301
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Heartburn and gastro-oesophageal reflux.
    Bennett JR
    Br J Clin Pract; 1991; 45(4):273-7. PubMed ID: 1810362
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Importance of reflux symptoms in functional dyspepsia.
    Small PK; Loudon MA; Waldron B; Smith D; Campbell FC
    Gut; 1995 Feb; 36(2):189-92. PubMed ID: 7883215
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Is this a reflux patient or is it a patient with functional dyspepsia with additional reflux symptoms?
    Funch-Jensen P
    Scand J Gastroenterol Suppl; 1995; 211():29-31. PubMed ID: 8545627
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Managing gastro-oesophageal reflux disease in the older patient.
    Hungin AP; Raghunath A
    Digestion; 2004; 69 Suppl 1():17-24. PubMed ID: 15001831
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Managing gastro-oesophageal reflux in infants.
    Drug Ther Bull; 2009 Dec; 47(12):134-7. PubMed ID: 20009040
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The impact of pre-endoscopy proton pump inhibitor use on the classification of non-erosive reflux disease and erosive oesophagitis.
    Gaddam S; Wani S; Ahmed H; Maddur P; Hall SB; Gupta N; Puli SR; Higbee A; Rastogi A; Bansal A; Sharma P
    Aliment Pharmacol Ther; 2010 Nov; 32(10):1266-74. PubMed ID: 20955446
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The predictive value of symptoms in gastro-oesophageal reflux disease.
    Berstad A; Hatlebakk JG
    Scand J Gastroenterol Suppl; 1995; 211():1-4. PubMed ID: 8545622
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Failure of reflux inhibitors in clinical trials: bad drugs or wrong patients?
    Kahrilas PJ; Boeckxstaens G
    Gut; 2012 Oct; 61(10):1501-9. PubMed ID: 22684485
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Relationship between gastro-oesophageal reflux and airway diseases: the airway reflux paradigm.
    Pacheco-Galván A; Hart SP; Morice AH
    Arch Bronconeumol; 2011 Apr; 47(4):195-203. PubMed ID: 21459504
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Minimal differences in prevalence and spectrum of organic disease at upper gastrointestinal endoscopy between selected secondary care patients with symptoms of gastro-oesophageal reflux or dyspepsia.
    Irvine AJ; Pinto-Sanchez MI; Bercik P; Moayyedi P; Ford AC
    Scand J Gastroenterol; 2017 Apr; 52(4):396-402. PubMed ID: 27973922
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Gastroesophageal reflux disease. Standards of the Czech Society of Gastroenterology--actualization 2009].
    Lukás K; Bures J; Drahonovský V; Hep A; Jirásek V; Mandys V; Martínek J; Richter P; Strosová A
    Vnitr Lek; 2009 Oct; 55(10):967-75. PubMed ID: 19947242
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.